Search Results
Your search for Andrew Evens, DO, MSc,Andrew Evens, DO, MSc matches 13 pages
Showing 1 - 13New Data May Inform Treatment of Pregnant Patients With Relapsed or Refractory Lymphoma
In a new study reported by Farooq et al in Blood Advances, patients with relapsed or refractory lymphoma during pregnancy had a progression-free survival rate of 24% and an overall survival rate of 83%. Background Receiving a lymphoma diagnosis during pregnancy may be uncommon but can occur for...
New Burkitt Lymphoma International Prognostic Index
As reported by Olszewski et al in the Journal of Clinical Oncology, members of The Burkitt Lymphoma International Prognostic Index Consortium have developed an index—the Burkitt Lymphoma International Prognostic Index (BL-IPI)—that provides “robust discrimination of survival” among adult patients...
International Consortium Aims to Enhance Decision-Making in Hodgkin Lymphoma
Harmonization of big data in examining acute and long-term outcomes with contemporary treatment for pediatric and adult patients with Hodgkin lymphoma is yielding a new approach to inform future clinical trial design and enhance clinical decision-making, according to a statement by Rutgers Cancer...
Sequential Brentuximab Vedotin and AVD in Older Patients With Newly Diagnosed Hodgkin Lymphoma
In a phase II study reported in the Journal of Clinical Oncology, Evens et al found that a regimen of brentuximab vedotin (Adcetris) given sequentially before and after standard doxorubicin, vinblastine, and dacarbazine (AVD) was associated with good outcomes in untreated older patients with...
Best Outcomes to Date in Older Patients With Hodgkin Lymphoma
Older patients with Hodgkin lymphoma typically do not fare as well as younger patients on standard regimens. A phase II study reported the best outcomes to date in older patients with Hodgkin lymphoma who were treated with sequential brentuximab vedotin (Adcetris) before and after a regimen of...
Intergroup Study Evaluates Outcomes of Elderly vs Younger Patients Treated for Advanced Hodgkin Lymphoma
The 11th International Conference on Malignant Lymphoma was held June 15–18 in Lugano, Switzerland. Topics of discussion included lymphoma staging in the new millennium, lymphoma and its microenvironment, and lymphoma cure vs control. The ASCO Post summarized several key presentations in the July...
Expert Point of View: Therapy for Hodgkin Lymphoma in the Elderly Remains Undefined
Elderly Hodgkin lymphoma, typically defined as affecting individuals ≥ 60 years of age, remains a disease for which no standard treatment recommendation exists. This population is underrepresented in clinical studies, and survival rates in older patients with Hodgkin lymphoma are significantly and ...
Therapy for Hodgkin Lymphoma in the Elderly Remains Undefined
At the 2011 Pan-Pacific Lymphoma Conference held recently in Kauai, Hawaii, Andrew M. Evens, DO, MSc, Director of the Lymphoma Program at the University of Massachusetts Medical School in Worcester, discussed Hodgkin lymphoma in elderly patients. Event-free survival and overall survival rates in...
Multicenter Analysis of Outcomes of Lymphoma in Pregnancy
Lymphoma is the fourth most frequent cancer to occur in pregnant women. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, Chief of Hematology/Oncology at Tufts University Medical Center, Boston, and colleagues examined treatment,...
Exciting Highlights in Several Types of Lymphoma Presented at Best of ASCO
Antibody-drug conjugates are being tested against several types of lymphomas and for some of these agents, “activity is quite impressive,” Andrew M. Evens, DO, MSc, reported at the recent Best of ASCO meeting in Chicago. Dr. Evens, Professor of Medicine, Chief, Division of Hematology/Oncology, and...
CAR T-Cell Therapy in Cancer: Driving Toward the Clinic
Chimeric antigen receptor (CAR) T-cell therapy represents a novel and promising therapeutic advance in cancer.1,2 It constitutes a form of personalized therapy that harnesses adoptive cell transfer through genetic engineering of autologous T cells. The initial step in this therapeutic paradigm...
CD19-Directed CAR T Cells Produce Sustained Remission in Relapsed/Refractory Acute Lymphoblastic Leukemia
In a study reported in The New England Journal of Medicine, Shannon L. Maude, MD, PhD, of Children’s Hospital of Philadelphia, and Noelle Frey, MD, of the Perelman School of Medicine, University of Pennsylvania, and colleagues reported achieving sustained remissions in children and adults with...
For Pregnant Women With Lymphoma, Standard Combination Chemotherapy Given After First Trimester Associated With Few Complications
Lymphoma is the fourth most frequent cancer to occur during pregnancy. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, of Tufts University Medical School, and colleagues examined treatment, complications, and outcomes for Hodgkin lymphoma...
